Safety, Tolerability and Preliminary Efficacy of Engineered Red Blood Cell in Patients With Advanced Malignancies
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This phase studies the engineered red blood cells with PD-1 inhibitor pembrolizumab（WTX212）,
the natural biological metabolic function of red blood cells can make the carried
pembrolizumab directionally distributed in the spleen tissue and activitate T cells,
suggesting that this product may solve the problem that PD-1 treatment failure.